NEW YORK, November 28, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members
with timely information WallStEquities.com has issued free tailored
Stock Review on SNY, DRRX, SCMP, and PRGO which is a click away at
http://www.wallstequities.com/registration. Charles Schwab reported that, in general,
Healthcare companies' balance sheets are solid, their stocks have
offered attractive dividend yields, and the sector's overall cost
structure appears to have improved. Demand appears to be on the
rise for health care products and services. Today,
WallStEquities.com reviews Sanofi (NYSE: SNY), DURECT Corp.
(NASDAQ: DRRX), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and
Perrigo Co. PLC (NYSE: PRGO). Free Downloads on Wall St. Equities
today, sign up now and access these stocks' research reports
at:
http://www.wallstequities.com/registration
Sanofi
Paris, France headquartered
Sanofi's stock finished Monday's session 1.06% lower at
$45.61. A total volume of 1.21
million shares was traded, which was above their three months
average volume of 1.16 million shares. The Company's shares have
gained 12.78% since the start of this year. The stock is trading
below its 200-day moving average by 3.44%. Moreover, shares of
Sanofi, which researches, develops, manufactures, and markets
therapeutic solutions, have a Relative Strength Index (RSI) of
43.62.
On November 02nd, 2017
at the 1st European ATTR Amyloidosis Meeting for
Patients and Doctors in Paris,
Sanofi Genzyme, a business unit of Sanofi, and Alnylam
Pharmaceuticals, Inc. (ALNY) announced positive complete results
from the APOLLO Phase 3 study of patisiran, an investigational RNAi
therapeutic being developed for patients with hereditary ATTR
amyloidosis with polyneuropathy. Based on these results, ALNY
intends to file a new drug application in the US for patisiran by
end-2017 and a marketing authorization application in the European
Union shortly thereafter.
On November 15th, 2017,
research firm Barclays upgraded the Company's stock rating from
'Underweight' to 'Equal Weight'. Free Access to this morning's
research report on SNY at:
http://www.wallstequities.com/registration/?symbol=SNY
DURECT
Shares in Cupertino, California
headquartered DURECT Corp. declined 0.89%, ending yesterday's
session at $1.11 with a total trading
volume of 603,470 shares. The stock has surged 42.36% in the past
month. The Company's shares are trading 15.31% below their 200-day
moving average. Moreover, shares of DURECT, which researches and
develops medicines based on its epigenetic regulator and drug
delivery programs, has an RSI of 50.86.
On November 01st, 2017,
DURECT announced its results for the three months
ended September 30th, 2017. Total revenues
were $20.7 million and net income was $6.1 million
for Q3 2017, as compared to total revenues of $3.7
million and net loss of $8.8 million for Q3 2016.
At September 30th, 2017, cash and investments
were $41.8 million, compared to cash and investments
of $25.2 million at December 31st, 2016.
Find your free research report DRRX at:
http://www.wallstequities.com/registration/?symbol=DRRX
Sucampo Pharmaceuticals
On Monday, Rockville, Maryland
headquartered Sucampo Pharmaceuticals Inc.'s stock climbed 0.95%,
to close the day at $10.65. A total
volume of 529,130 shares was traded, which was above their three
months average volume of 492,570 shares. The Company's shares have
advanced 10.36% in the last one month. The stock is trading 0.15%
below its 50-day moving average. Additionally, shares of Sucampo
Pharma, which focuses on developing, identifying, acquiring, and
marketing medicines that meet unmet medical needs, primarily in
gastroenterology, ophthalmology, and oncology-related disorders in
the US, Japan, Switzerland, and internationally, have an RSI
of 53.44.
On November 14th, 2017,
research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the
Company's stock, with a target price of $14 per share.
On November 21st, 2017,
Sucampo Pharma announced that it will participate in a fireside
chat at the 29th Annual Piper Jaffray Healthcare
Conference on November
28th, 2017, at 11:30 a.m.
ET. The fireside chat will be webcast live and may be
accessed under the Event Calendar page of the Company's website.
Sign up today for the free research report on SCMP at:
http://www.wallstequities.com/registration/?symbol=SCMP
Perrigo
Shares in Dublin, Ireland
headquartered Perrigo Co. PLC ended the day 0.59% lower at
$86.06. A total volume of 859,354
shares was traded. The stock has gained 3.02% in the last one
month, 9.81% in the previous three months, and 3.40% since the
start of this year. The Company's shares are trading above their
50-day and 200-day moving averages by 0.54% and 12.04%,
respectively. Furthermore, shares of Perrigo, which together with
its subsidiaries, develops, manufactures, markets, and distributes
over-the-counter consumer goods and pharmaceutical products
worldwide, have an RSI of 53.54.
On November 02nd, 2017,
Perrigo announced that its Board of Directors declared a quarterly
dividend of $0.16 per share, payable on December
19th, 2017, to shareholders of record
on December 01st, 2017.
On November 10th, 2017,
research firm RBC Capital Markets upgraded the Company's stock
rating from 'Underperform' to 'Sector Perform' while revising its
previous target price from $64 a
share to $86 a share. Wall St.
Equities' research coverage also includes the downloadable free
report on PRGO at:
http://www.wallstequities.com/registration/?symbol=PRGO
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. WSE has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
WSE has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@wallstequities.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by WSE. WSE is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. WSE, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, WSE, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither WSE nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore
228
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Wall St. Equities